Bernard Munos, MS, MBA: How to Use Informatics to Activate Innovation Pathways in Pharmaceutical R&D
The depth of the innovation crisis that threatens the pharmaceutical industry raises questions about innovation, such as where does it comes from, and how to get more of it? In this presentation, Bernard Munos, the author of several highly-cited papers on this subject, will review the four pathways that have historically produced breakthrough innovation, and a fifth one, the target-based drug discovery model, that is presently used by much of the industry. Using examples, he will show why the latter is unlikely to deliver, and why the industry must return to the other evidence-based innovation models. Throughout the presentation, he will highlight how informatics can be used to improve what works, and explain what does not. He will also sketch how innovation networks can be harnessed to revive drug discovery, achieve better risk mitigation, and make innovation more affordable.
Bernard Munos is the founder of the InnoThink Center for Research in Biomedical Innovation, which was created to translate innovation research into better evidence-based business models for the pharmaceutical industry and its stakeholders. Before that, he was Advisor for corporate strategy at Eli Lilly and Company where he focused on disruptive innovation and the radical redesign of the R&D model. His work, which has been published in Nature and Science, and was recently profiled by Forbes Magazine, has helped stimulate a broad rethinking of the pharmaceutical business model by companies, investors, policy-makers, regulators, and patient advocates.
He has presented his findings at numerous meetings sponsored by the National Academies, the Institute of Medicine, the President’s Cancer Panel, the NIH Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the US Patent and Trademark Office, Genome Canada, the American Chemical Society, the Council for American Medical Innovation, as well as leading universities and think-tanks in the US and Europe.
He received his MBA from Stanford University, and holds other graduate degrees in economics and animal science from the University of California at Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences in France.